Barry Marshall – Rationale for #Vaccine Delivery: Choosing the right strain from human studies

In Therapeutic Vaccines by Maria RelakiLeave a Comment

Barry Marshall - OndekThe Nobel Prize Winner Dr Barry Marshall joined us at the World Vaccine Congress in Washington DC in April this year to share his views on his mission to use the HPPT delivery
platform for vaccines, biologics and immunotherapeutics.

 

In 2005 Barry J. Marshall and J. Robin Warren were awarded the Nobel Prize for Physiology or Medicine in recognition of their 1982 discovery that a bacterium, Helicobacter pylori, causes one of the most common and important diseases of mankind, peptic ulcer disease.   Marshall's early research included a famous self experiment whereby he drank a culture of Helicobacter in order to fulfill Koch's postulates for the bacterium.  He rediscovered the acute infectivity syndrome of Helicobacter and the development of gastritis, the precursors to peptic ulcer.  Marshall is Clinical Professor of Microbiology and Medicine at the University of Western Australia in Perth.

 

Dr Marshall introduced the Helicobacter pylori platform technology (HPPT) and discussed its unique potential as an oral delivery system.

 

Furthermore, he presented early Phase I clinical data on candidate H. pylori recipient strains in humans and specifically showed data on infectivity, safety and immunogenicity.

 

The discussion then continued around future Phase I trials for an Influenza GMO HPPT vaccine in humans and the possibilities this might open up.

 

To get Barry Marshall's entire presentation on the H. pylori platform technology for vaccine development, please click here and let us know what you think.

Leave a Comment

Current ye@r *